Clinical Research Philadelphia | Philadelphia, PA

Research site

About

Clinical Research Philadelphia (CRP) is the region’s most experienced dedicated site, completing 500+ trials since 1996. Operating across two locations and multiple therapeutic areas, our veteran team delivers excellence through a fully electronic infrastructure (CRIO eSource/eReg). We drive rapid, diverse recruitment via AI-based EMR mining and a network of 70+ provider partnerships accessing 300,000+ patients. From start-up to database lock, CRP combines decades of expertise with tech-enabled execution to provide sponsors with unmatched speed, quality, and transparency.

Location

9501 Roosevelt Boulevard, Suit 208, Philadelphia, Pennsylvania, United States of America

Website

https://www.phillyresearch.com/

Site insights

Top conditions

Top treatments

Amlitelimab

Mesafem

BAY3427080

Elinzanetant

Tranexamic Acid

SAR444656

progestin

Vilaprisan

Ustekinumab

VeraCept

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Aneesh Vaze

Verified by this site

Active trials

9 of 28 total trials

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (EMBARQ-CSU1)

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling

Chronic Spontaneous Urticaria

Biological: barzolvolimab

Biological: Matching placebo

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis (READY-AD)

The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).

Enrolling

Dermatitis, Atopic

Drug: JNJ-95597528

Drug: Placebo

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ASCEND)

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to sev...

Active, not recruiting

Plaque Psoriasis

Drug: Ustekinumab

Drug: Matching Placebo to Ustekinumab

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis (VELOTA)

The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with ac...

Enrolling

Arthritis, Psoriatic

Drug: JNJ-88545223

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participant...

Enrolling

Dermatitis Atopic

Drug: Amlitelimab

Drug: Topical corticosteroids

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Active, not recruiting

Dermatitis Atopic

Drug: Placebo

Drug: Amlitelimab

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER-AD)

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate t...

Invitation-only

Dermatitis Atopic

Drug: Topical calcineurin inhibitors

Drug: Topical corticosteroids

Nipocalimab in Moderate to Severe Sjogren's Disease (DAFFODIL)

The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (S...

Enrolling

Sjogrens Syndrome

Drug: Placebo

Drug: Standard of care treatment

Locations recently updated

Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

The Sponsor is developing a progestin-only contraceptive transdermal system (patch).The main purpose of this study is to look at how safe the study p...

Enrolling

Female Contraception

Drug: Transdermal system containing progestin